低危患者外科主动脉瓣置换术的结局:瓣膜技术评估基准
该研究分析2010至2015年18家心脏中心2505例孤立性主动脉瓣置换术,其中2138例STS预测死亡风险低于4%,1119例符合PARTNER 3标准。低危患者手术死亡1.3%、永久卒中1.3%、起搏器植入4.2%,最常见不良事件为输血≥2单位(18%)和房颤(28%),中位住院6天、总费用37,999美元。
要点
- 低危患者外科AVR手术死亡1.3%、永久卒中1.3%。
- 最常见并发症为房颤(28%)和输血≥2单位(18%)。
- 中位住院6天,中位总费用37,999美元。
核心结论
- 当代低危患者行外科主动脉瓣置换术结果优异,最常见并发症为房颤和出血。
研究设计与样本
- 回顾性分析2010至2015年18家州立心脏机构2505例孤立性AVR,其中2138例STS预测死亡风险低于4%,1119例符合PARTNER 3标准。
主要发现
- 研究合格患者中位STS预测死亡风险1.44%,中位年龄72岁(IQR 65-78)。
- 手术死亡1.3%,永久卒中1.3%,起搏器植入4.2%。
- 输血≥2单位红细胞18%,房颤28%,中位住院6天(IQR 5-8)。
- 中位总住院费用37,999美元(IQR 30,671-46,138)。
- 年龄<65岁与≥65岁相比,输血(11.2%,p<0.001)和房颤(17.1%,p<0.001)显著更低,手术死亡(2.2% vs 0.9%,p=0.1)、主要并发症(10.4% vs 12.6%,p=0.3)和总费用无差异。
关键数值与推荐
- 研究纳入标准包括STS预测死亡风险<4%及符合PARTNER 3方案的其他临床和血流动力学标准。
- 排除心内膜炎、终末期肾病、射血分数<0.45、二叶瓣和既往瓣膜置换患者。
临床怎么用
- 为低危主动脉瓣狭窄患者的外科AVR提供了真实世界结局和费用基准,可用于与经导管AVR临床试验数据对比。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two large, randomized trials are underway evaluating transcatheter aortic valve replacement (AVR) against conventional surgical AVR. We analyzed contemporary, real-world outcomes of surgical AVR in low-risk patients to provide a practical benchmark of outcomes and cost for evaluating current and future transapical AVR technology. METHODS: From 2010 to 2015, 2,505 isolated AVR operations were performed for severe aortic stenosis at 18 statewide cardiac institutions. Of these, 2,138 patients had a Society of Thoracic Surgeons predicted risk of mortality of less than 4%, and 1,119 met other clinical and hemodynamic criteria as outlined in the PARTNER 3 (The Placement of Transcatheter Aortic Valves) protocol. Patients with endocarditis, end-stage renal disease, ejection fraction of less than 0.45, bicuspid valves, and previous valve replacements were excluded. Outcomes of interest included operative death and postoperative adverse events. RESULTS: The median Society of Thoracic Surgeons predicted risk of mortality for the study-eligible patients was 1.44%, with a median age of 72 years (interquartile range [IQR], 65 to 78 years). Operative mortality was 1.3%, permanent stroke was 1.3%, and pacemaker requirement was 4.2%. The most common adverse events were transfusion of 2 or more units of red blood cells (18%) and atrial fibrillation (28%). The median length of stay was 6 days (IQR, 5 to 8 days). Median total hospital cost was $37,999 (IQR, $30,671 to $46,138). Examination of complications by age younger than 65 vs 65 or older demonstrated a significantly lower need for transfusion (11.2%, p < 0.001) and incidence of atrial fibrillation (17.1%, p < 0.001) but no difference in operative mortality (2.2% vs 0.9%, p = 0.1), major morbidity (10.4% vs 12.6%, p = 0.3), or total hospital costs. CONCLUSIONS: Low-risk patients undergoing surgical AVR in the current era have excellent results. The most common complications were atrial fibrillation and bleeding. These real-world results should provide additional context for upcoming transcatheter clinical trial data.
引用
- Johnston LE, Downs EA, Hawkins RB, et al. Outcomes for Low-Risk Surgical Aortic Valve Replacement: A Benchmark for Aortic Valve Technology. Ann Thorac Surg. 2017. PMID: 28610884. doi:10.1016/j.athoracsur.2017.03.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。